Вирус гепатита С 3-го генотипа: такой "простой", такой "сложный"


Цитировать

Полный текст

Аннотация

Аннотация. Представлены данные о естественном течении и эффективности терапии хронического гепатита С, вызванного вирусами различных генотипов. Обсуждается роль генотипа вируса в прогрессировании фиброза и формировании стеатоза печени. Отмечается, что хронический гепатит С, вызванный вирусом 3-го генотипа, характеризуется более агрессивным течением и менее благоприятным прогнозом. Определены оптимальные подходы к ведению больных хроническим гепатитом С, вызванного вирусом 3-го генотипа, а также перспективы противовирусной терапии у пациентов данной категории.

Полный текст

Вирус гепатита С 3-го генотипа: такой "простой", такой "сложный". - Аннотация. Представлены данные о естественном течении и эффективности терапии хронического гепатита С, вызванного вирусами различных генотипов. Обсуждается роль генотипа вируса в прогрессировании фиброза и формировании стеатоза печени. Отмечается, что хронический гепатит С, вызванный вирусом 3-го генотипа, характеризуется более агрессивным течением и менее благоприятным прогнозом. Определены оптимальные подходы к ведению больных хроническим гепатитом С, вызванного вирусом 3-го генотипа, а также перспективы противовирусной терапии у пациентов данной категории.
×

Об авторах

С Н Бацких

ФБУН "Центральный НИИ эпидемиологии" Роспотребнадзора

Email: zdoc@mail.ru
111123 Москва, ул. Новогиреевская, 3а

С В Морозов

ФГБУ "НИИ питания" РАМН, Москва

Email: morosoffsv@mail.ru

В П Чуланов

ФБУН "Центральный НИИ эпидемиологии" Роспотребнадзора

Email: vladimir.chulanov@pcr.ru

В И Покровский

ФБУН "Центральный НИИ эпидемиологии" Роспотребнадзора

Email: info@crie.ru

Список литературы

  1. Shepard C.W., Finelli L., Alter M.J. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558-567.
  2. Simmonds P., Bukh J., Combet C. et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005; 42 (4): 962-973.
  3. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011; 17 (2): 107-115.
  4. Пименов Н.Н., Чуланов В.П., Комарова С.В. и др. Гепатит С в России: эпидемиологическая характеристика и пути совершенствования диагностики и надзора. Эпидемиол и инфекц бол 2012; 3: 4-10.
  5. Соринсон С.Н. Особенности патогенеза и течения гепатита С. Оптимальные сроки лечения интерфероном. Вирусные гепатиты: достижения и перспективы 1998; 1: 3-8.
  6. Poynard T., Bedossa P., Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349: 825-832.
  7. Seeff L.B. Natural history of hepatitis C. Am J Med 1999; 107: S10-S15.
  8. Deuffic-Burban S., Poynard T., Valleron A.J. Quantification of fibrosis progression in patients with chronic hepatitis C using a Markov model. J Viral Hepat 2002; 9: 114-122.
  9. Serfaty L., Poujol-Robert A., Carbonell N. et al. Effect of the interaction between steatosis and alcohol intake on liver fibrosis progression in chronic hepatitis C. Am J Gastroenterol 2002; 97: 1807-1812.
  10. Wiley T.E., McCarthy M., Breidi L., Layden T.J. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology 1998; 28: 805-809.
  11. Nousbaum J.B., Pol S., Nalpas B. et al. Hepatitis C virus type 1b (II) infection in France and Italy. Collaborative Study Group. Ann Intern Med 1995; 122: 161-168.
  12. Silini E., Bono F., Cividini A. et al. Differential distribution of hepatitis C virus genotypes in patients with and without liver function abnormalities. Hepatology 1995; 21: 285-290.
  13. Zein N.N., Rakela J., Poterucha J.J. et al. Hepatitis C genotypes in liver transplant recipients: distribution and 1-year follow-up. Liver Transpl Surg 1995; 1 (6): 354-357.
  14. Féray C., Gigou M., Samuel D. et al. Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation. Gastroenterology 1995; 108: 1314-1317.
  15. Castera L., Hezode C., Roudot-Thoraval F. et al. Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. Gut 2003; 52: 288-292.
  16. Czaja A.J., Carpenter H.A., Santrach P.J., Moore S.B. Host- and disease-specific factors affecting steatosis in chronic hepatitis C. J Hepatol 1998; 29: 198-206.
  17. Bochud P.Y., Cai T., Overbeck K. et al. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis. J Hepatol 2009; 51 (4): 655-666.
  18. Westin J., Nordlinder H., Lagging M. et al. Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. J Hepatol 2002; 37: 837-842.
  19. Rubbia-Brandt L., Fabris P., Paganin S. et al. Steatosis affects chronic hepatitis C progression in a genotype specific way. Gut 2004; 53 (3): 406-412.
  20. De Nicola S., Aghemo A., Rumi M.G., Colombo M. HCV genotype 3: an independent predictor of fibrosis progression in chronic hepatitis C. J Hepatol 2009; 51 (5): 964-966.
  21. Fartoux L., Chazouillères O., Wendum D. et al. Impact of steatosis on progression of fibrosis in patients with mild hepatitis C. Hepatology 2005; 41 (1): 82-87.
  22. Kasprzak A., Zabel M., Biczysko W. et al. Expression of cytokines (TNF-α, IL-1α, and IL-2) in chronic hepatitis C: Comparative Hybridocytochemical and Immunocytochemical Study in children and adult patients. J Histochem Cytochem 2004; 52 (1): 29-38.
  23. Leandro G., Mangia A., Hui J. et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006; 130: 1636-1642.
  24. Cua I.H., Hui J.M., Kench J.G., George J. Genotype-specific interactions of insulin resistance, steatosis, and fibrosis in chronic hepatitis C. Hepatology 2008; 48 (3): 723-731.
  25. Younossi Z.M., McCullough A.J., Ong J.P. et al. Obesity and non-alcoholic fatty liver disease in chronic hepatitis C. J Clin Gastroenterol 2004; 38 (8): 705-709.
  26. Asselah T., Rubbia-Brandt L., Marcellin P., Negro F. Steatosis in chronic hepatitis C: why does it really matter? Gut 2006; 55 (1):123-130.
  27. Browning J.D., Szczepaniak L.S., Dobbins R. et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40 (6):1387-1395.
  28. Nomura H., Kashiwagi S., Hayashi J. et al. Prevalence of fatty liver in a general population of Okinawa, Japan. Jpn J Med 1988; 27 (2): 142-149.
  29. Hwang S.J., Luo J.C., Chu C.W. et al. Hepatic steatosis in chronic hepatitis C virus infection: prevalence and clinical correlation. J. Gastroenterol Hepatol 2001; 16: 190-195.
  30. Tsutsumi T., Suzuki T., Shimoike T. et al. Interaction of hepatitis C virus core protein with retinoid X receptor a modulates its transcriptional activity. Hepatology 2002; 35: 937-946.
  31. Hourioux C., Patient R., Morin A. et al. The genotype 3-specific hepatitis C virus core protein residue phenylalanine 164 increases steatosis in an in vitro cellular model. Gut 2007; 56: 1302-1308.
  32. Perlemuter G., Sabile A., Letteron P. et al. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J 2002; 16: 185-194.
  33. Jackel-Cram C., Babiuk L.A., Liu Q.J. Up-regulation of fatty acid synthase promoter by hepatitis C virus core protein: genotype-3a core has a stronger effect than genotype-1b core. Hepatology 2007; 46 (6): 999-1008.
  34. Kim K.H., Hong S.P., Kim K. et al. HCV core protein induces hepatic lipid accumulation by activating SREBP1 and PPARc. Biochem Biophys Res Commun 2007; 355 (4): 883-888.
  35. Okuda M., Li K., Beard M.R. et al. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 2002; 122: 366-375.
  36. Abid K., Pazienza V., De Gottardi A. et al. An in vitro model of hepatitis C virus genotype 3a-associated triglycerides accumulation. J Hepatol 2005; 42: 744-751.
  37. Grassi A., Ballardini G., Susca M. et al. HCV liver infection and liver steatosis: evidence for indirect mechanisms in genotype 3? Aliment Pharmacol Ther 2005; 22: 79-82.
  38. Asselah T., Boyer N., Marcellin P. Steatosis in hepatitis C: what does it mean? Gastroenterol Clin Biol 2003; 27 (12): 1073-1075.
  39. Fartoux L., Poujol-Robert A., Guechot J. et al. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 2005; 54: 1003-1008.
  40. Adinolfi L.E., Gambardella M., Andreana A. et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 1358-1364.
  41. Hui J.M., Kench J., Farrell G.C. et al. Genotype specific mechanisms for hepatic steatosis in chronic hepatitis C infection. J Gastroenterol Hepatol 2002; 17: 873-881.
  42. Hezode C., Roudot-Thoraval F., Zafrani E.S. et al. Different mechanisms of steatosis in hepatitis C virus genotypes 1 and 3 infections. J Viral Hepat 2004; 11: 455-458.
  43. Patton H.M., Patel K., Behling C. et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 2004; 40: 484-490.
  44. Kumar D., Farrell G.C., Fung C., George G. Hepatitis C virus genotype 3 is cytopathic to hepatocytes: reversal of hepatic steatosis after sustained therapeutic response. Hepatology 2002; 36 (5): 1266-1272.
  45. Rubbia-Brandt L., Quadri R., Abid K. et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 2000; 33: 106-115.
  46. Barba G., Harper F., Harada T. et al. Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. Proc. Natl Acad. Sci. USA 1997; 94: 1200-1205.
  47. Jhaveri R., McHutchison J., Patel K. et al. Specific polymorphisms in hepatitis C virus genotype 3 core protein associated with intracellular lipid accumulation. J Infect Dis 2008; 197: 283-291.
  48. Moriya K., Nakagawa K., Santa T. et al. Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis. Cancer Res 2001; 61: 4365-4370.
  49. Nkontchou G., Ziol M., Aout M. et al. HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis. J Viral Hepat 2011; 18: 516-522.
  50. Della Rossa A., Tavoni A., Baldini C., Bombardieri S. Mixed cryoglobulinemia and hepatitis C virus association: ten years later. Isr Med Assoc J 2001; 3 (6): 430-434.
  51. Ramos-Casals M., Forns X., Brito-Zerón P. et al. Cryoglobulinaemia associated with hepatitis C virus: influence of HCV genotypes, HCV-RNA viraemia and HIV coinfection. J Viral Hepat 2007; 14 (10): 736-742.
  52. Parise E.R., de Oliveira A.C., Ferraz M.L. et al. Cryoglobulinemia in chronic hepatitis C: clinical aspects and response to treatment with interferon alpha and ribavirin. Rev Inst Med Trop Sao Paulo 2007; 49 (2): 67-72.
  53. Vigani A.G., Pavan M.H., Tozzo R. et al. Comparative study of patients with chronic hepatitis C virus infection due to genotypes 1 and 3 referred for treatment in southeast Brazil. BMC Infect Dis 2008; 8: 164.
  54. Manns M.P., McHutchison J.G., Gordon S.C. et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358 (9286): 958-965.
  55. Fried M.W., Shiffman M.L., Reddy K.R. et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347 (13): 975-982.
  56. Andriulli A., Mangia A., Iacobellis A. et al. Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis. Aliment Pharmacol Ther 2008; 28 (4): 397-404.
  57. Shah S.R., Patel K., Marcellin P. et al. Steatosis is an independent predictor of relapse following rapid virologic response in patients with HCV genotype 3. Clin Gastroenterol Hepatol 2011; 9: 688-693.
  58. Hadziyannis S.J., Sette H. Jr., Morgan T.R. et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140 (5): 346-355.
  59. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. J Hepatol 2011; 55: 245-264.
  60. Sarin S.K., Kumar C.K. Treatment of patients with genotype 3 chronic hepatitis C - current and future therapies. Liver Int 2012; 32 Suppl 1: 141-145.
  61. Ge D., Fellay J., Thompson A.J. et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461 (7262): 399-401.
  62. Moghaddam A., Melum E., Reinton N. et al. IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection. Hepatology 2011; 53: 746-754.
  63. Mangia A., Thompson A.J., Santoro R. et al. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology 2010; 139 (3): 821-827.
  64. Ghany M.G., Nelson D.R., Strader D.B. et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 1433-1444.
  65. Brainard D.M., Petry A., Van Dyck K. et al. Safety and antiviral activity of MK-5172, a novel HCV NS3/4a protease inhibitor with potent activity against known resistance mutants, in genotype 1 and 3 HCV-infected patients. Program and abstracts of the 61st Annual Meeting of the American Association for the Study of Liver Diseases; October 29 - November 2, 2010; Boston, Massachusetts. Abstract 807.
  66. Gane E.J., Rodriguez-Torres M., Nelson D.E. et al. Sustained virologic response (SVR) following RG7128 1500 mg BID/PEG-IFN/RBV for 28 days in HCV genotype 2/3 prior non-responders. Program and abstracts of the 45th Annual Meeting of the European Association for the Study of the Liver; April 14-18, 2010; Vienna, Austria. Abstract 37.
  67. Sulkowski M., Gardiner D., Lawitz E. et al. Potent viral suppression with all-oral combination of daclatasvir (NS5A inhibitor) and GS-7977 (NS5B inhibitor), ± ribavirin, in treatment-naive patients with chronic HCV GT1, 2, or 3. Program and abstracts of the 47th Annual Meeting of the European Association for the Study of the Liver; April 18-22, 2012; Barcelona, Spain. Abstract 1422.
  68. Ramos E.L. Preclinical and clinical development of pegylated interferon-lambda 1 in chronic hepatitis C. J Interferon Cytokine Res 2010; 30 (8): 591-595.
  69. Muir A.J., Shiffman M.L., Zaman A. et al. Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology 2010; 52 (3): 822-832.
  70. Zeuzem S., Arora S., Bacon B. et al. Peginterferon lambda-1a (lambda) compared to peginterferon alfa-2a (alfa) in treatment-naive patients with HCV genotypes (G) 2 or 3: first SVR24 results from EMERGE phase IIB. Program and abstracts of the 47th Annual Meeting of the European Association for the Study of the Liver; April 18-22, 2012; Barcelona, Spain. Abstract 10.
  71. Flisiak R., Horban A., Gallay P. et al. The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus. Hepatology 2008; 47: 817-826.
  72. Pawlotsky J.M., Sarin S.K., Foster G. et al. Alisporivir plus ribavirin is highly effective as interferon-free or interferon-add-on regimen in previously untreated HCV-GT2 or GT3 patients: SVR12 results from VITAL-1 phase 2b study. Program and abstracts of the 47th Annual Meeting of the European Association for the Study of the Liver; April 18-22, 2012; Barcelona, Spain. Abstract 1405.
  73. Flisiak R., Feinman S.V., Jablkowski M. et al. The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naive hepatitis C patients. Hepatology 2009; 49: 1460-1468.
  74. Pawlotsky J.M., Flisiak R., Rasenack J. et al. Once daily alisporivir interferon (IFN)-free regimens achieve high rates of early HCV clearance in previously untreated patients with HCV genotype (G) 2 or 3. Program and abstracts of the 62nd Annual Meeting of the American Association for the Study of Liver Diseases; November 4-8, 2011; San Francisco, California. Abstract LB-11.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО "Консилиум Медикум", 2012

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Адрес издателя

  • 127055, г. Москва, Алабяна ул., 13, корп.1

Адрес редакции

  • 127055, г. Москва, Алабяна ул., 13, корп.1

По вопросам публикаций

  • +7 (926) 905-41-26
  • editor@ter-arkhiv.ru

По вопросам рекламы

  • +7 (495) 098-03-59

 

  


Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах